A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
EP171/#1044 Beside breast/ovarian malignancy: other cancer risk profile in BRCA1 and BRCA2 pathogenic variants
2022
E-Posters
unpublished
105, 18%), does not want to discuss GT with family (55, 9%), relatives not interested (50, 9%), language (38, 7%), and other (27, 5%). Of 73 enrolled patients, 45 (62%) contacted at least one relative to discuss GT within two months of enrollment. Twelve patients had at least one relative who participated in our facilitated referral pathway, but only 2 (3%) relatives completed GT through our pathway. Two additional relatives underwent GT separately. Of 20 patients who completed 3-month
doi:10.1136/ijgc-2022-igcs.262
fatcat:szj7v2dh4vdzrdcfhbtgxz2wya